Segment Information - Schedule of Financial Information by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Net sales	$ 3,935,000	$ 5,935,000
Gross profit	1,932,000	1,909,000
Direct expenses	54,670,000	36,568,000
Segment contribution	(52,738,000)	(34,659,000)
Indirect expenses	(11,132,000)	6,955,000
Income (loss) from operations	(63,870,000)	(41,614,000)
Components of other
Change in fair value of contingent consideration liability	(18,932,000)	4,849,000
Change in fair value of contingent stock consideration	(110,000)	1,565,000
Goodwill impairment	29,633,000	0
Cell Therapy
Segment Reporting Information [Line Items]
Direct expenses	40,162,000	21,213,000
Segment contribution	(40,162,000)	(21,213,000)
Components of other
Goodwill impairment	29,633,000
Biobanking
Segment Reporting Information [Line Items]
Net sales	1,357,000	1,283,000
Gross profit	885,000	335,000
Direct expenses	344,000	626,000
Segment contribution	541,000	(291,000)
Degenerative Disease
Segment Reporting Information [Line Items]
Net sales	2,578,000	4,652,000
Gross profit	1,047,000	1,574,000
Direct expenses	3,009,000	1,459,000
Segment contribution	(1,962,000)	115,000
Other
Segment Reporting Information [Line Items]
Direct expenses	11,155,000	13,270,000
Segment contribution	(11,155,000)	(13,270,000)
Indirect expenses	(11,132,000)	6,955,000
Components of other
Change in fair value of contingent consideration liability	(18,932,000)	4,849,000
Change in fair value of contingent stock consideration	(110,000)	1,565,000
Goodwill impairment	29,633,000
Amortization	541,000	541,000
Total other	$ 11,132,000	$ 6,955,000